Behringwerke Aktiengesellschaft

Hoechst Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Sanofi-aventis Pharma Deutschland Gmbh

Laboratories Hoechst S.a.

Laboratoires Hoechst

Paal, Michael

Kolar, Cenek

Hermentin, Peter

Kraemer, Hans P.

Cenek Kolar

Hans P Kraemer

Klaus Bosslet

Dieter Hoffmann

Gerhard Seemann

Peter Hermentin

Wolfgang Konig

Hans-Harald Sedlacek

Gerhard Dickneite

Jean-Claude Jacquesy

Michael Paal

Jurgen K Sandow

Claude Monneret

Michel Koch

Manfred Gerken

Jean-Pierre Gesson

Jean-Claude Florent

Francedillaois Tillequin

Konrad Dehmel

Werner Stuber

Jorg Czech

Hans G Berscheid

Dirk Bottger

Michel Azoulay

Rainer Koschinsky

Dieter Hoffman

J&ouml;rg Czech

Hans-Matthias Deger

Ulrich Stache

Joachim Thiem

Hans H Sedlacek

Hans-Ulrich Schorlemmer

Friedrich R Seiler

Hans Paulsen

Matthias Kreuzer

Martine Mondon

J Org Czech

Jörg Czech

Werner St Uber

Ernst Raab

Gilbert Gaudel

Brigitte Renoux

Jean C Jacquinet

Ursula Knodler

Hans Peter Kraemer

Hans Gerd Berscheid

The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.

Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates

Glycosyl-spacer-drugs compounds (prodrugs), their preparation and their use as pharmaceuticals are described.

Prodrugs, their preparation and use as pharmaceuticals

Prodrugs their preparation and use as pharmaceuticals

Amidinophenylalanine derivatives of the formula I ##STR1## the synthesis of these compounds, the use thereof and pharmaceutical agents which contain these compounds are described.

Amidinophenylalanine derivatives, a process for the preparation thereof,

Glycosylated prodrugs, their method of preparation and their uses

Glycopeptide derivatives, a process for their preparation and pharmaceutical agents containing these compounds N-Glycopeptide derivatives of the formula I ##STR1## where aromatic is an unsubstituted or substituted benzene residue, naphthalene residue, chroman residue, chromene residue or coumarone residue,

Glycopeptide derivatives, a process for their preparation and

Peptides of the formula ##STR1## in which X is alkanoyl, A is optionally substituted D-Nal(2), D-Phe or D-Trp, B is optionally substituted D-Phe, C is D-Pal(3) or optionally substituted D-Phe or D-Trp, and D is Tyr or His, E is D-Ser (R.sup.1), F is Leu, Trp or Phe, G is L-Ser(R.sup.1), H is Gly-NH.sub.2, D-Ala-NH.sub.2 or Azagly-NH.sub.2 and R.sup.1 is a glycosyl radical. These peptides have an inhibitory effect on the formation of the gonadotropins lutropin and follitropin and thus also on the synthesis of testo-sterone and estrogen. A process for the preparation of these peptides is described.

Gonadoliberin antagonists

The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I, ##STR1## which can optionally also be in the form of an acid addition salt of physiologically acceptable inorganic or organic acids, where R.sup.1 is hydrogen or a hydroxyl group, R.sup.2 is hydrogen, a hydroxyl or a methoxy group, R.sup.3 is hydrogen or a hydroxyl group, R.sup.4 is hydrogen or a hydroxyl group, R.sup.5 hydrogen, a hydroxyl or a methoxycarbonyl group, R.sup.6 is CH.sub.2 CH.sub.3, COCH.sub.3, COCH.sub.2 OH, CHOHCH.sub.3 or CHOHCH.sub.2 OH and R.sup.7 is an organic substituent which has 2 to 6 carbon atoms and which contains at least one oxygen, nitrogen or sulfur atom or a C--C double bond or a C--C triple bond, it being possible for the double bond also to be a constituent of a heteroaromatic system and for the oxygen, nitrogen or sulfur atom to be a constituent of an open-chain or heterocyclic system, to a process for the preparation thereof and to the use thereof in a pharmaceutical.

Anthracycline derivatives having cytostatic activity

The invention relates to peptides of the formula ##STR1## in which X is absent or is hydrogen or acyl; A is Pgl, de-hydro-Pro, Pro, D-Thi or D-Pgl or represents optionally substituted D-Nal(2), D-Phe or D-Trp; B is His or optionally substituted D-Phe; C is Trp, D-Thi, D-Pal(3) or optionally substituted D-Trp; D is Tyr, Arg of His; E is D-Ser(R.sup.1), .beta.-Asn, .beta.-Asp-OMe, D-Thi or --NH--CH(CH.sub.2 R.sup.2)--CO--; F is Ser(R.sup.1), Leu, Trp or Phe; G is Gly-NH.sub.2, Aza-Gly-NH.sub.2, D-Ala-NH.sub.2 or NH-alkyl; R.sup.1 is glycosyl and R.sup.2 is hydrogen, acyl, aryl or heteroaryl. The invention also relates to methods for the preparation of these peptides, agents containing them and their use.

Analogs of gonadoliberin with improved solubility, methods for their

Compounds of the general formula I ##STR1## in which R.sup.1 represents a hydrogen atom or an alkyl group of the formula CH.sub.3 (CH.sub.2).sub.n --where n=0 to 5,

Cis-platinum complexes, a process for the preparation thereof, and

Competitive gonadoliberin antagonists

7-O-Glycosyl-rhodomycins which correspond to the general formula I below ##STR1## in which the radicals have the following meaning: R.sup.1 is a hydrogen atom or a hydroxyl group,

Rhodomycins with a modified carbohydrate unit

Growing community of inventors

Marburg, Germany

Cenek Kolar